Little has been written about reimbursement in the era of big data–driven personalized medicine. The way the United States pays for the majority of its health care is a hindrance to the provision of personalized oncology care.
No takes yet. Share an insight, caveat, or question.
Jeffery C. Ward (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: